ONCOMATRYX
Agent36Agent Readiness: 36/100. Below median. Measured by StartupHub.ai. Median 41.Trust73Data Trust: 73/100. Above median. Measured by StartupHub.ai. Median 61.Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.
About this profileCompany details: from public sourcesFunding: no announced round on fileOwnership: not yet claimed by the companyScores: measured by named tools; each links to its methodOur rules
About
ONCOMATRYX is a Spanish biopharmaceutical company focused on developing innovative cancer therapies. They specialize in Quantum ADCs (Antibody-Drug Conjugates) designed to target the tumor microenvironment. The company has recently secured significant funding to advance the clinical development of its novel drug candidates.
Listed competitors
A global oncology company developing and commercializing innovative cancer treatments.
Global biopharmaceutical company focused on oncology and neuroscience treatments.
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Also in this space
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Shares Biotechnology, Pharmaceuticals
A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.
Shares Biotechnology, Biotech
Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
Shares Biotechnology, Biotech
Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
Shares Biotechnology, Pharmaceuticals
Leveraging AI and a massive patient tissue dataset to accelerate drug discovery and advance precision medicine.
Shares Biotechnology, Drug Discovery
Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.
Shares Biotechnology, Drug Discovery
Key facts
- Website
- oncomatryx.com
- Headquarters
- Derio, Spain
- Founded
- 2009
- Employees
- 36
- Total funding
- $107M (Funding Round)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 30 Mar 2026 | Funding Round | $67M | |
| 29 Jan 2026 | Series C | $27M | |
| 14 Jul 2025 | Grant/Equity | $13M | European Innovation Council (EIC) Accelerator |
Tech stack
Detected on oncomatryx.com, last scanned 1 Nov 2026. Run your own scan
- Hosting
- Google Cloud
- Email provider
- Microsoft 365
ONCOMATRYX scores 37. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is ONCOMATRYX trustworthy and reputable?
StartupHub's Data Trust & Reputation score for ONCOMATRYX is 73 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has ONCOMATRYX raised?
ONCOMATRYX has raised a total of $107M in funding. The most recent round on record is Funding Round.
How many employees does ONCOMATRYX have?
ONCOMATRYX has approximately 36 people on record.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for ONCOMATRYX
